|
Ipsen is a French pharmaceutical company headquartered in Paris, France.〔(Official website, Key Figures ). Ipsen.com.〕 It primarily develops and markets medications used in oncology, endocrinology and the treatment of neuromuscular disorders.〔 It is publicly traded on the Euronext Paris as part of the SBF 120 index.〔 ==Overview== Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2012. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urology-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. The Beaufour family, which ranks as the 42nd richest family in France, still owns 68% of its share, and two of its members, Anne and Henri Beaufour, sit on its board of directors.〔(Challenges wealth ranking ). Challenges.fr.〕〔(Challenges ). Challenges.fr.〕〔(Board of Directors ). Ipsen.com.〕 Its chairman and chief executive officer is Marc de Garidel.〔(Marc de Garidel's biography ). Ipsen.com.〕 In 2012, Ipsen spent close to €250 million—20 % of consolidated sales—on research and development, according to the IFRS. In February 2015, the company announced it would Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbex’s lead multiple sclerosis compound, VSN16R.〔http://www.genengnews.com/gen-news-highlights/ipsen-gains-option-to-buy-canbex-therapeutics-for-6-8m/81250959/〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Ipsen」の詳細全文を読む スポンサード リンク
|